Arkolith/Insider Trading/CTNM/Form 4

Stengone Carmine N.

CEO and President, DirectorContineum Therapeutics, Inc. (CTNM) · full profile →Form 4 · filed Jul 1, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$160K
Net Open-Market Flow
-$160K
Transactions
5
3 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)8K$1.01$8K25K
Jun 30, 2026Option exercise(M)3K$1.26$3K27K
Jun 30, 2026Sell(S)10K$16.01$160K17K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 30, 2026Option exercise(M)8K—$0282K
Jun 30, 2026Option exercise(M)3K—$0118K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-046653) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML

Keep exploring

Connected pages for Contineum Therapeutics, Inc.

Build

Ask your agent about CTNM insider filings

This filing is the Follow view. The Build view lets your agent pull every Form 4 for the issuer, the net open-market picture over 90 days, and the accession behind each row, through REST or MCP.

Get a key Compare plansForm 4 data
Copy-paste
curl -H "Authorization: Bearer YOUR_API_KEY" \
  "https://arkolith.com/api/v1/filing/0001628280-26-046653"
Ask your agent
Use Arkolith to summarize insider buying and selling at Contineum Therapeutics, Inc.
over the last 90 days and cite the filings.